On June 25, 2025, D. Boral Capital reaffirmed its commitment to CytoSorbents (CTSO, Financial), maintaining both the stock's rating and its price target. The analyst, Jason Kolbert, has kept a 'Buy' rating on the stock, reflecting a continued positive outlook.
The current price target for CytoSorbents (CTSO, Financial) remains steady at $10.00 USD. This target is unchanged from the previous assessment, indicating the analyst's consistent confidence in the company's performance and potential.
For investors and stakeholders of CytoSorbents (CTSO, Financial), this sustained recommendation serves as a key indicator of the stock's projected stability and growth. As the market evolves, maintaining such guidance can be crucial for decision-making and portfolio strategy.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for CytoSorbents Corp (CTSO, Financial) is $5.00 with a high estimate of $10.00 and a low estimate of $1.00. The average target implies an upside of 316.67% from the current price of $1.20. More detailed estimate data can be found on the CytoSorbents Corp (CTSO) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, CytoSorbents Corp's (CTSO, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for CytoSorbents Corp (CTSO, Financial) in one year is $1.42, suggesting a upside of 18.33% from the current price of $1.2. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the CytoSorbents Corp (CTSO) Summary page.
